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ABSTRACT
The development of drug resistance following treatment with chemotherapeutic 
agents such as cisplatin (cis) and paclitaxel (pax) contributes to high morbidity and 
mortality in ovarian cancers. However, the molecular mechanisms underlying such 
changes are not well understood. In this study, we demonstrate that the Brn-3b 
transcription factor was increased in different ovarian cancer cells including SKOV3 
and A2780 following treatment with cis and pax. Furthermore, sustained increases 
in Brn-3b were associated with survival in drug resistant cells and correlated with 
elevated HSP27 expression. In contrast, targeting Brn-3b for reduction using short 
interfering RNA (siRNA) also resulted in attenuated HSP27 expression. Importantly, 
blocking Brn-3b expression with siRNA in SKOV3 cells was associated with reduced 
cell numbers at baseline but also increased cell death after further treatment, 
indicating sensitization of cells. Similar results were obtained in the metastatic 
IP1 cell line derived from ascites of mice bearing SKOV3 tumours. These findings 
suggest that increased Brn-3b may confer resistance to chemotherapeutic drugs 
in ovarian cancer cells by regulating key target genes such as HSP27 and that 
targeting Brn-3b may provide a novel mechanism for treatment of drug resistant 
ovarian cancers.
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INTRODUCTION
Ovarian cancers are the seventh most common 
cancers in women worldwide but have high mortality, 
with 5 year survival of 30–50% [1]. Such high mortality 
arises in part due to the silent nature of this disease since 
many symptoms are shared with other common conditions 
[2]. Consequently only ~15–20% of ovarian cancers are 
diagnosed at stage I, when the disease is limited to the 
ovaries and responds effectively to treatments such as 
surgery. In the majority of cases, patients present with 
more advanced disease that has spread beyond the ovary to 
involve the pelvic organs (stage II), abdomen (stage III) or 
beyond the peritoneal cavity (stage IV), which have poor 
prognosis and reduced survival rates [3, 4]. 
Such advanced diseases are commonly treated with 
a combination of surgery and chemotherapeutic drugs such 
as cisplatin and paclitaxel, which have been established as 
first line treatment of such cancers [5, 6]. However, drug 
resistance remains a major problem particularly in the 
higher stage cancers because despite initial responsiveness 
to treatment, the majority of patients eventually relapse 
with drug-resistant cancer [7–9] which accounts for >90% 
mortality in patients with metastatic diseases. 
The molecular basis by which ovarian cancer cells 
acquire drug resistance and metastatic potential are not 
fully understood but such complex processes are highly 
dependent on changes in cellular genes that enhance 
survival and confer migratory potential. In this regard, 
transcription factors which regulate the expression of 
multiple, tissue-specific target genes will be important 
for driving such events in cancer cells. Brn-3b is a POU 
(Pit-Oct-Unc) homeodomain transcription factor, which 
has been implicated in regulating diverse tumorigenic 
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processes in breast cancer and childhood neuroblastomas. 
For instance, Brn-3b overexpression enhances cell 
proliferation in vitro and tumour growth in vivo [10] 
while reducing Brn-3b is sufficient to inhibit proliferation 
and slow tumour growth [11]. However, Brn-3b is also 
induced following treatment with chemotherapeutic 
drugs such as cisplatin and high levels also confer drug 
resistance and increased migratory potential [11, 12]. 
In line with this, Brn-3b protein is elevated in >60% of 
breast cancers and >70% of childhood neuroblastomas 
[13, 14].
As a transcription factor, Brn-3b mediates such 
diverse effects by complex regulation of multiple target 
genes. For example, the growth promoting effects of 
Brn-3b are associated with transactivation of cell cycle 
proteins cyclinD1/CDK4 [14, 15] and repression of the 
tumour suppressor gene BRCA1 [13], which inhibits the 
cell cycle or activates apoptosis in breast cancer cells. In 
contrast, when Brn-3b is increased in response to drug 
treatment, it regulates distinct subsets of genes that can 
cause different cellular responses. For instance, Brn-
3b represses the expression of the adhesion molecule 
γ-catenin (plakoglobin) [16] which normally represses 
growth and migration of cancer cells [17] but strongly 
activates the small heat-shock protein, HSP27 which 
increases migration in cancer cells but also confers 
protection from apoptosis [18]. In fact, cooperation 
between Brn-3b and the oestrogen receptor (ER) is 
required for maximal stimulation of HSP27 in breast 
cancer cells suggesting that this transcription factor is 
important in driving HSP27 expression. HSP27 has been 
implicated in metastatic ovarian cancers and is considered 
as a predictor of poor survival in patients with ovarian 
tumours [19, 20]. Furthermore, reducing HSP27 in 
ovarian cancer cells confers increased sensitivity to drugs 
such as paclitaxel suggesting that increased expression 
of this heat-shock protein will be relevant for conferring 
drug resistance [21].
In this study, we demonstrated that Brn-3b protein 
expression was increased in human ovarian cancer cell 
lines such as SKOV3 and A2780 following treatment with 
chemotherapeutic drugs such as cisplatin and paclitaxel, 
which are commonly used for treatment of ovarian cancers. 
Sustained increases in Brn-3b protein was detected in 
drug-resistant SKOV3 cells either induced by chronic drug 
treatment (>2 weeks) or in established SKOV3-IP1 cells. 
In drug resistant cells, elevated Brn-3b levels correlated 
with expression of its known target gene, HSP27, whereas 
blocking Brn-3b using short interfering RNA (siRNA) 
resulted in loss of HSP27 expression. Furthermore, Brn-3b 
siRNA reduced cell viability at baseline but also sensitised 
cells to drug treatment. These results and potential 
implications for controlling the growth of ovarian cancer 
cells and responses to chemotherapeutic treatment are 
discussed here.
RESULTS 
Induction of POU4F2/Brn-3b in ovarian cancer 
cells by cisplatin 
Since increased Brn-3b in neuroblastoma cells 
confers resistance to chemotherapeutic drugs such as 
cisplatin [11], which are commonly used with paclitaxel as 
first-line chemotherapeutic treatment of ovarian cancers, 
we were interested in studying Brn-3b expression in 
ovarian cancer cell lines following treatment with cisplatin 
and/or paclitaxel. The ovarian adenocarcinoma cell line, 
SKOV3 was used for preliminary studies in which MTT 
cell viability assays were undertaken to establish the 
optimal dose and time course for treatment (see Figure 1A). 
For individual drug treatment, increasing doses of cisplatin 
or paclitaxel were used as specified but for combination 
treatment, (cis+pax), 1 µg/ml paclitaxel was used while 
cisplatin was increased as specified. This was necessary to 
avoid high toxicity caused by increasing paclitaxel dosage. 
The results showed that while cisplatin treatment had a 
small effect on cell viability after 24 hours, increased 
doses of paclitaxel either alone or in combination caused 
reduced cell viability. Since combination therapies 
are more commonly used to treat ovarian cancers, all 
subsequent studies were undertaken using paclitaxel 
(1 µg/ml) + cisplatin (5 µg/ml) which caused consistent 
and reproducible cell loss (30–40%) by 24 hours. 
To analyse for changes in Brn-3b expression 
following treatment, western blot analyses were 
undertaken using protein extracts prepared from 
SKOV3 cells that were either untreated (control) or 
treated as indicated. Figure 1B(i) shows a representative 
western blot demonstrating that Brn-3b was expressed 
at low levels in untreated cells  but was increased 
following drug treatment for 24 hours. Treatment 
with paclitaxel or cis-pax combination caused 
significant increases in Brn-3b expression after 24 h 
when compared with untreated controls while cisplatin 
only treatment resulted in smaller changes. Two Brn-3b 
protein isoforms (l) and, (s) exist and while Brn-3b(l) was 
found at lower levels in untreated cells, both isoforms were 
increased following drug treatment. GAPDH antibodies 
and/ or β-tubulin levels were used to determine variation 
in protein loading between different samples. 
Similar studies were carried out to analyse Brn-3b 
expression in protein extracts from untreated and drug 
treated A2780 cells, a high-grade serous ovarian cancer 
cell line. Figure 1C(i) shows a representative western blot 
which demonstrated lower Brn-3b protein expression in 
untreated control cells which was increased following 
drug treatment especially after cis + pax combination. 
However, protein levels appear to be lower than SKOV3 
cells and only the shorter Brn-3b(s) protein was detected 
in these cells. 
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Immunofluorescence staining and fluorescent 
imaging were also carried out in SKOV3 and A2780 to 
confirm Brn-3b expression and to analyse for cellular 
localization in these cells with and without drug 
treatment. Representative images shown in Figure 1B 
(ii) demonstrates that low levels of Brn-3b protein in 
untreated SKOV3 was significantly increased following 
treatment with cis + pax (lower panel). As expected 
for a transcription factor, protein localisation appears 
to be mainly in the cell nuclei while lower levels in the 
cytoplasm may reflect newly synthesized proteins that 
have not yet been imported into the cell nuclei. Similar 
expression patterns were detected in A2780 [Figure 1C 
(ii)] confirming lower protein expression in untreated cells 
which is increased following drug treatment. Similar to 
SKOV3 cells, Brn-3b was primarily localised in the cell 
nuclei of drug treated A2780 cells, when compared with 
untreated controls. 
Brn-3b expression in drug resistant SKOV3 cells
Increased Brn-3b was previously linked to survival 
following drug treatment and invasiveness in other cancers 
[11]. Therefore, we next tested if Brn-3b expression 
Figure 1: Brn-3b induction in drug treated SKOV3 cells. (A) Results of MTT assays showing changes in viability of SKOV3 
cells following treatment with different doses of cisplatin or paclitaxel (0–20 µg/ml) and combination of paclitaxel (1 µg/ml) and increasing 
cisplatin, as indicated. The percentage of viable cells following different treatments is expressed relative to control untreated cells, set 
at 100%. Values represent mean and standard error from three independent experiments each with at least three separate treatment sets. 
(B) (i) Representative western blots showing Brn-3b expression in untreated SKOV3 control cells and experimental cells treated with 
cisplatin (5 µg/ml) or paclitaxel (1 µg/ml) alone or combination of cis + pax (5 µg/ml +1 µg/ml). β-tubulin was used to control for 
protein loading. (ii) Representative immunofluorescence staining shows localisation of Brn-3b proteins in SKOV3 cells treated with 
drug combination (cisplatin + paclitaxel) for 24 h. Brn-3b protein was detected using FITC conjugated secondary Ab (green) and DAPI 
staining indicates the cell nuclei. (C) (i) Representative western blots showing Brn-3b expression in untreated A2780 control cells and 
experimental cells treated with cisplatin (5 µg/ml) or paclitaxel (5 µg/ml) alone or combination of cis + pax (5 µg/ml +1 µg/ml). GAPDH 
immunoblot was used to control for protein loading and was similar to another invariant protein, β-tubulin (not shown). (ii) Representative 
immunofluorescence staining shows localisation of Brn-3b proteins in A2780 cells treated with drug combination (cis + pax) for 24 h. Brn-
3b protein was detected using FITC conjugated secondary Ab (green) and DAPI staining indicates the cell nuclei.
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was sustained in drug resistant SKOV3 cells which 
were grown under selection pressure for >2 weeks (see 
methods). Protein extracts from drug resistant cells were 
analysed for changes in Brn-3b expression using western 
blotting and a representative blot shown in Figure 2A 
(i) demonstrates that drug resistant cells expressed 
higher  levels of Brn-3b protein when compared with 
untreated controls. Quantification of multiple experiments 
(n = 5) showed statistically significant increases in Brn-
3b in drug resistant SKOV3 cells, when compared with 
untreated controls (p value < 0.05) [Figure 2A (ii)]. 
Figure 2B shows representative immunofluorescent 
staining of drug resistant cells grown on coverslips, which 
confirmed Brn-3b protein localisation in drug resistant 
cells (green). Bright field imaging displayed distinct 
morphological features of drug resistant cells including 
flattened cells with significant projections and large nuclei.
We also analysed Brn-3b expression in the metastatic 
IP1, which was derived from ascites of mice bearing 
SKOV3 tumours). Figure 2C shows a representative 
immunostaining image which demonstrated that Brn-3b 
was highly expressed in untreated cells but with increased 
intensity following drug treatment (cis + pax). When taken 
together with data from drug resistant cells, these results 
suggest that Brn-3b may be associated with drug resistance 
and metastasis in ovarian cancers also.
Known Brn-3b target, HSP-27, closely correlates 
with Brn-3b expression
The small heat-shock protein, HSP27 is a known 
Brn-3b target gene [18] and in fact Brn-3b was shown 
to be required for maximal expression of HSP27 in drug 
treated breast cancer cells. Since HSP27 is strongly 
Figure 2: (A) (i) Representative western blot analysis showing increased Brn-3b protein expression in drug resistant cells compared with 
untreated control cells. (ii) Quantification of Brn-3b protein adjusted for β-tubulin in cisplatin resistant (drug-resistant) cells compared with 
control cells (set at 1). *Indicates statistical increase in Brn-3b protein (P < 0.05, student’s t test). (B) Representative immunofluorescence 
staining for Brn-3b proteins in drug resistant SKOV3 cells (2 weeks). Brn-3b protein was detected using FITC conjugated secondary Ab 
(green) and DAPI staining indicates the cell nuclei. Phase contrast microscopy shows the cell morphology in bright field. (C) Representative 
immunofluorescence staining for Brn-3b proteins in metastatic SKOV3-IP1 either in untreated controls or following drug treatment with cis 
+ pax. Brn-3b protein was detected using FITC conjugated secondary Ab (green) and DAPI staining indicates the cell nuclei. 
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associated with aggressive ovarian cancers that has poor 
prognosis and reduced survival [20], we next tested if Brn-
3b expression correlated with HSP27 expression in ovarian 
cancer cells also. Therefore, co-immunofluorescent 
staining was carried out in drug treated SKOV3 cells to 
analyse for co-expression of HSP27 and Brn-3b. Figure 3A 
shows that at the cellular level drug treated SKOV3 cells 
(i) or SKOV3 -IP3 cells (ii) which express nuclear Brn-3b 
(green) also expressed HSP27 (red) in the cytoplasm. 
To determine if Brn-3b was required for HSP27 
expression in these cells, we next tested if reducing 
Brn-3b expression in SKOV3 cells would also reduce 
HSP27 expression. Brn-3b reduction was achieved using 
MISSION® short interfering RNA (siRNA) (Sigma, UK) 
designed to target Brn-3b protein and a non-silencing 
(NS) siRNA sequence was used as controls for these 
experiments. Different amounts (6, 30 and 60 pmol) of 
MISSION® siRNA were transfected into SKOV3 cells 
and changes in Brn-3b protein expression were analysed 
by western blotting. Figure 3B shows that 30–60 pmol of 
Brn-3b SASI_HS01_00087301 siRNA (referred to as Brn-
3b siRNA-301) could effectively and reproducibly reduce 
Brn-3b levels after 72 hours and as such 30 pmol was 
used for subsequent studies (see below). Importantly, cells 
transfected with Brn-3b siRNA expressed significantly 
reduced HSP27 protein compared with NS siRNA (middle 
panel). This was also confirmed by co-immunostaining 
studies since cells transfected with Brn-3bsiRNA-301 did 
not express HSP27 proteins whereas NS siRNA transfected 
cells clearly co-expressed Brn-3b and HSP27 (Figure 3C). 
These results suggest that Brn-3b may be involved in 
regulating HSP27 in ovarian cancer cells also and thereby 
contribute to drug resistance and metastatic potential in 
these cells. 
Figure 3:  (A) Representative immunofluorescence staining for Brn-3b and HSP27 proteins in SKOV3 cells (i) or IP1 cells following 
drug treatment. Brn-3b protein was detected using FITC conjugated secondary Ab (green) and DAPI staining indicates the cell nuclei. (B) 
Representative western blot of SKOV3 cells transfected with Brn-3b siRNA-301 or non-silencing controls (NS siRNA) showing reduction 
of Brn3b protein levels and reduced HSP27 protein levels in cells transfected with Brn3b siRNA-301. β-tubulin blots were used to show 
variability in protein loading in different samples. (C) Representative immunofluorescence staining for Brn-3b and HSP27 proteins in 
SKOV3 cells transfected with Brn-3b siRNA-301 or non-silencing controls (NS siRNA) showing reduction of Brn3b protein levels and 
reduced HSP27 protein levels in cells transfected with Brn3b siRNA 301. Brn-3b protein was detected using FITC conjugated secondary 
Ab (green) whereas HSP27 Ab was detected using PE conjugated secondary Ab (red). DAPI staining indicates the cell nuclei. Images were 
captured at 40× magnification.
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siRNA silencing of Brn-3b expression reduces 
cell viability in SKOV3 or IP1 cells
To determine if Brn-3b was required for cell survival 
following drug treatment, we next tested if reducing Brn-
3b expression affected cell fate. Therefore, SKOV3 cells 
were transfected with different concentrations of Brn-3b 
siRNA or NS siRNA (6 and 30 pmol) for 72 h. After 72 h, 
cells were either left untreated or treated with cis + pax 
combination for 24 h and cell viability was then analysed 
using MTT assay. Figure 4A shows percentage of viable 
cells under different conditions relative to untreated control, 
set at 100%. Non-silencing NS siRNA had minimal effects 
on cell viability in untreated cells but drug treatment caused 
an expected reduction in cell numbers. In contrast, Brn-3b 
siRNA-301 was sufficient to reduce cell numbers even in 
untreated cells (54% ± 9 at 6 pmol and 40% ± 13 at 30 pmol) 
when compared with the appropriate non-silencing control 
siRNA (86% ± 17 at 6 pmol and 75.3% ± 11 at 30 pmol) 
(P < 0.05). In addition, treatment with chemotherapeutic 
drugs caused significant loss of cells transfected with Brn-
3b siRNA (28% ± 9 at 6pmol and 21% ± 10 at 30 pmol) 
(P < 0.001). These results strongly suggest that reducing 
Brn-3b was sufficient to prevent proliferation and/ or reduce 
viability of SKOV3 ovarian cancer cells alone but when 
reduction of Brn-3b was combined with drug treatment, 
this resulted in significant loss of cells when compared with 
non-silencing control cells treated with drugs.
Similar studies were undertaken using the 
aggressive and metastatic IP1 sub-line, which was derived 
from ascites of mice injected with SKOV3. As before, 
cells were transfected with non-silencing (NS) control 
siRNA or Brn-3b siRNA and then either left untreated or 
treated with drug combination (cis + pax) for 24 hours. 
Results of MTT assays showed that treatment with cis 
+ pax had little effect on reducing viability of control 
IP1 cells (Figure 4B), suggesting drug resistance when 
compared with the parental SKOV3 cells. However, 
Figure 4: (A) Results of pooled MTT assays to analyse for changes in cell viability in SKOV3 cells transfected with Brn-3b siRNA-301 
or non-silencing controls (NS siRNA) for 72 hours followed by treatment with cisplatin and paclitaxel (5 µg/ml +1 µg/ml). Results are 
expressed relative to untreated cells, where absorbance was set at 100 and changes in viability of cells transfected with NS siRNA or 
Brn-3b siRNA 301 are expressed relative to the control. Values represent the mean ± standard error from three independent experiments. 
(***P < 0.001, two-way ANOVA). (B) MTT assays to analyse for changes in cell viability in IP1 cells transfected with Brn-3b siRNA-301 
for 72 hours followed by treatment with cisplatin and paclitaxel (5 µg/ml + 1 µg/ml). Results are expressed relative to untreated NS siRNA 
cells, where absorbance was set at 100.
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siRNA that targeted Brn-3b caused loss in cell viability 
even in untreated cells and more marked reduction in cell 
survival following drug treatment. Therefore similar to the 
SKOV3 cells, reducing Brn-3b increases sensitivity of a 
more aggressive, metastatic cell line to drug treatment.
DISCUSSION
The acquisition of drug resistance by cancer cells 
is a major hurdle in treatment of patients with ovarian 
cancers since it underlies the recurrence of cancer cells 
that become intractable to treatment. This can profoundly 
affect outcome since it is associated with poor prognosis 
and reduced survival but the molecular mechanisms 
associated with such changes are not fully understood 
[9, 22]. The Brn-3b transcription factor is a master 
regulator that can control the expression of multiple target 
genes in a cell specific or growth condition dependent 
manner. It has been implicated in different tumourigenic 
processes in breast cancer and neuroblastoma cells since 
overexpression of this protein can enhance cell growth 
in vitro and tumour growth in vivo but also alter behaviour 
of the cells by increasing anchorage independent growth 
[10, 11]. Conversely, reducing Brn-3b was sufficient 
to inhibit cell proliferation in vitro and tumour growth 
in vivo. However, Brn-3b is also increased in cells 
treated with chemotherapeutic drugs such as cisplatin or 
doxorubicin and, under such conditions, Brn-3b can confer 
survival and resistance to treatment while increasing cell 
migration and metastatic potential [11, 12, 18]. 
Brn-3b has also been detected in ovarian cancer 
cells but its expression and effects in these cells have not 
been reported previously. In this study, we demonstrate 
that Brn-3b protein is increased in different ovarian cancer 
cells including SKOV3 and A2780, following treatment 
with common chemotherapeutic agents, cisplatin and 
paclitaxel. Analysis of SKOV3 cells shows that low Brn-3b 
levels in untreated cells is significantly increased in 
response to drug treatment particularly when using the 
combination of cisplatin and paclitaxel, commonly used 
for treatment of patients with ovarian cancers. The gene 
encoding Brn-3b can give rise to 2 protein isoforms, 
thought to arise from alternative promoter usage, which 
results in inclusion of an additional N-terminal domain 
in the longer Brn-3b(l) protein that is not present in the 
shorter Brn-3b(s) isoform [23, 24]. Interestingly, our data 
has shown distinct patterns of Brn-3b protein isoforms in 
ovarian cancer cells. For instance, the shorter isoform, 
Brn-3b(s) isoform is detected in both cell lines following 
drug treatment but appears to be the only isoform in 
A2780 cells. In contrast, the longer Brn-3b(l) isoform is 
detectable at low levels in untreated SKOV3 cells but 
also increases following drug treatment. Although the 
implications of such distinct expression patterns are still 
to be elucidated, previous studies have shown that Brn-
3b(s) is increased in breast cancers or neuroblastoma 
tumours and its overexpression in breast cancer or 
neuroblastoma derived cell lines is sufficient to enhance 
growth and transformation [10, 11] but also confer 
resistance to chemotherapeutic drugs including cisplatin 
and doxorubicin [12]. As such, induction of the shorter 
Brn-3b (s) isoform following drug treatment of ovarian 
cancer cells may suggest that this protein will have similar 
effects in ovarian cancer cells also. 
It is notable that, Brn-3b appears to be expressed 
at higher levels in SKOV3 cells, which are derived from 
metastatic cells in ascites taken from a patient with 
ovarian adenocarcinoma when compared with A2780, 
which was generated from primary ovarian endometrial 
adenocarcinoma. Since high levels of Brn-3b can confer 
drug resistance and migratory potential in breast cancer 
cells following treatment [18], we considered if this 
protein could have similar roles in controlling growth 
and behaviour of ovarian cancer cells also. In line with 
this, drug resistant SKOV3 cells, which were grown 
continuously in low doses of cis + pax treatment for >2 
weeks, expressed high levels of Brn-3b, suggesting that 
this regulator may have potential roles in the acquisition 
of drug resistance in ovarian cancer cells. This is also 
supported by studies carried out in the highly metastatic 
SKOV3-IP1 sub line, which expressed Brn-3b at baseline 
but showed increased expression following drug treatment. 
Therefore, Brn-3b may regulate genes associated with 
drug resistance and migration, similar to its effects in other 
cancers [11, 18].
Previous studies have identified multiple Brn-3b 
target genes in cancer cells but whilst activation of target 
genes such as cyclin D1/CDK4 and repression of BRCA1 
tumour suppressor are likely to contribute to growth and 
proliferation in cancer cells, the small heat shock protein, 
HSP27 was the main Brn-3b target gene, known to be 
associated with survival following drug treatment and 
increased metastasis. In this regard, Brn-3b is known 
to be a potent activator of HSP27 since it can directly 
activate the gene promoter but also co-operates with the 
oestrogen receptor (ER) to maximally stimulate HSP27 
expression. Moreover, Brn-3b levels in biopsies taken 
from breast cancer patients also show strong correlation 
with elevated HSP27 expression. In vitro studies in breast 
cancer cell lines have also shown that Brn-3b is required 
for HSP27 expression in doxorubicin treated cells [12], 
since shRNA to silence Brn-3b was sufficient to block 
HSP27 expression. In this study, we demonstrate that in 
drug treated SKOV3 cells, high Brn-3b levels correlated 
well with induction of HSP27 protein. More importantly, 
siRNA to target Brn-3b resulted in loss of HSP27 protein 
confirming that Brn-3b may also regulate its expression in 
ovarian cancer cells.
In ovarian cancers, HSP27 is strongly implicated 
in survival, acquisition of drug resistance and metastatic 
potential in aggressive tumours [25]. Furthermore, 
knockdown of HSP-27 using siRNA has been shown to 
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increase sensitivity to chemotherapeutic drugs such as 
paclitaxel in ovarian cancer cells [21], suggesting that 
expression of this heat shock protein is important for 
conferring survival effects in drug treated cells. Its pro-
survival effects may arise from the ability of HSP27 
to protect cells from apoptosis by inhibiting apoptosis 
through mitochondrial mediated caspase-3 dependent 
pathways or membrane (Fas) induced apoptosis [26]. In 
patients with epithelial ovarian cancers, increased serum 
expression of HSP27 correlated with peritoneal metastasis 
[19, 20] and elevated HSP27 is considered as a predictor of 
poor survival in patients with ovarian tumours. Therefore, 
high Brn-3b levels in ovarian cancers may cause increased 
expression of such target genes and thereby confer drug 
resistance and/or increased metastatic potential.
Finally, our data show that Brn-3b is required for 
survival of SKOV3 ovarian cancer cells because siRNA 
to reduce Brn-3b can result in loss of cell viability 
in untreated cells but more importantly, reducing 
Brn-3b appears to confer increased sensitivity to 
chemotherapeutic drugs. Similarly, Brn-3b is expressed 
at high levels in the aggressive, metastatic IP1 sub-line, 
derived from ascites in mice injected with SKOV3 cells. 
Drug treatment of IP1 cells targeted with the non-silencing 
siRNA had little effect on cell viability suggesting that 
these cells had increased resistance to treatment compared 
with the parental SKOV3 cells, reducing Brn-3b using 
siRNA was sufficient to reduce cell viability but also 
increased sensitivity to drug treatment. These findings 
may be highly relevant to drug resistant cancers because 
whilst many patients show robust responsiveness to early 
chemotherapeutic treatment, the majority of patients 
develop relapsed drug resistant cancer which become 
refractory to subsequent treatment [8]. 
This is the first report showing that increased Brn-3b 
transcription factor may be important for controlling growth 
and behaviour of human ovarian cancer cells, particularly 
following treatment with common chemotherapeutic 
agents such as cisplatin and paclitaxel. These results, when 
combined with data from studies in other cancer related 
models [10–14, 18, 27], points to an important role for Brn-
3b in promoting survival and drug resistance in ovarian 
cancer cells. Based on its known function, the effects of 
Brn-3b and growth and behaviour of cancer cells are likely 
to be mediated by its ability to regulate the expression of 
multiple target genes that drive specific cellular effects. 
However whilst its growth promoting effects are linked to 
transactivation of cell cycle target genes such as cyclin D1 
[14, 15] and repression of tumour suppressor genes such 
as BRCA1 [13], its effects in drug treated cells are likely 
to be driven by activation of the small heat-shock protein, 
HSP27 [18] which can confer protection against apoptosis 
and accumulation of DNA damage e.g. caused by reactive 
oxygen species (ROS) [26, 28]. Its effects on diverse target 
genes may explain why reducing Brn-3b can sensitize cells 
to further chemotherapeutic treatment. 
Although Brn-3b expression in different ovarian 
cancers and its mechanism of action in initiation and 
progression of this disease are still to be elucidated, our 
results suggest that increased expression of this regulator 
can contribute to survival and drug resistance in ovarian 
cancer cells following chemotherapy. As such, Brn-3b may 
provide a novel but important therapeutic target that for 
the treatment of recurrent drug-resistant ovarian cancers, 
which contribute to the deadly nature of this disease. 
MATERIALS AND METHODS
Cell culture
Human SKOV3 ovarian adenocarcinoma cells 
(ATCC HTB-77™) were grown in full growth medium 
[McCoy’s 5A medium with 10% foetal bovine serum + 
1% penicillin-streptomycin (Gibco, Invitrogen)]. Human 
SKOV3-IP1cells were derived from the ascetic fluid of mice 
bearing SKOV3 tumours and for clarity will be referred 
to as IP1 cells. Cells were grown in full growth medium 
[RPMI medium with 10% foetal bovine serum + 1% 
penicillin-streptomycin (Gibco, Invitrogen)]. Human A2780 
ovarian (epithelial) carcinoma cells (Sigma, 93112519) 
were also cultured in full growth medium [RPMI medium 
with 10% foetal bovine serum + 1% penicillin-streptomycin 
(Gibco, Invitrogen)]. SKOV3 iP1 and A2780 cells were 
provided by Dr. Timothy Witney, University College 
London. Cells were maintained in a humidified atmosphere 
at 37° C and 5% CO2 and sub-cultured upon reaching 
70–80% confluence. For experiments, cells were plated in 
6-well (1–5 × 105 cells /well) or 12-well cell culture plates 
(1–5 × 104 cells/well) prior to other protocols/treatments. 
Dose-response studies were used to establish the effects 
of different amounts of chemotherapeutic drugs, either 
alone or together, on cell viability and gene expression. For 
studies with the drug combinations, 1 µg/ml of paclitaxel 
was used with increasing amounts of cisplatin because 
at higher doses, paclitaxel in combination with cisplatin 
resulted in more significant cell death than similar doses 
alone. For generating drug-resistant cells, SKOV3 cells 
were treated with 1 µg/ml paclitaxel and 5 µg/ml cisplatin 
for 24 hours to kill off the most sensitive cells after which 
cells were maintained in medium containing 1 µg/ml of 
cis + 0.1 µg/ml pax. Medium with fresh drug was changed 
every 2–3 days for the duration of up to or > 2 weeks.
Transfection with short interfering RNA (siRNA) 
to reduce gene expression
Different pre-designed MISSION® siRNAs 
(Sigma, UK) were tested for effects on reducing Brn-
3b expression in SKOV3 cells by transfecting different 
amounts of siRNA (6, 30 and 60 pmol), using the 
MISSION® siRNA Transfection Reagent, in accordance 
with the manufacturer’s protocol. This was compared 
Oncotarget36778www.oncotarget.com
with cells transfected with an unrelated non-silencing 
siRNA that was used as a control. Western blot analysis 
of total cellular proteins taken at different times (72–
96 hours) after transfection was used to determine 
effectiveness of knockdown. In addition, to study the 
effects of chemotherapeutic drugs after reduction of 
Brn-3b, transfected cells were treated with different drug 
combinations for 24 hours before further analysis (e.g. 
MTT assays). 
Protein extraction and immunoblotting
Proteins harvested from SKOV3, IP1 and A2780 cells 
(in 2X Laemmli buffer) were resolved by 12% SDS-PAGE 
and used for immunoblotting as described (7). Briefly, 
membranes were blocked for 1 h in phosphate-buffered 
saline containing 0.1% Tween 20 (PBST)/4% non-fat 
powdered milk. Primary antibody (1:1000 dilution) was 
incubated overnight at 4° C or for 2–3 h at room temperature 
(RT). Following 5x washes with PBST, secondary antibody 
(1:2000) was incubated for 1 h (RT). Blots were developed 
using enhanced chemiluminescence reagent (Pearce, UK). 
Differences in total protein levels were adjusted using 
housekeeping genes, e.g. β-tubulin or GAPDH.
MTT assays for cell viability 
MTT assays were used to assess changes in live cells 
by determining the rate at which viable cells can reduce 
the tetrazolium dye [3-(4, 5 dimethylthizol-2-yl) 2–5 
diphenyltetrazolium bromide] to its insoluble formazan 
salt. These assays were undertaken using standard 
protocols whereby treated cells and untreated controls 
(SKOV3, IP1 and A2780 cell lines) were incubated with 
250 μl of 0.5 mg/ml of MTT for 2 hrs at 37° C. Following 
aspiration of MTT, formazan crystals were dissolved 
in 200 μl DMSO and optical density was measured by 
absorbance spectrometry at 560 nm.
Immunofluorescence
SKOV3, SKOV3 iP1 and A2780 cells were grown 
on coverslips and treated with cis+pax for 24 h. Cells were 
fixed in 4% paraformaldehyde (PFA) for 15 min, washed 
in 1X Phosphate-buffered saline (PBS) and pre-incubated 
in block solution [20% goat serum in PBS + 0.1% 
triton-X100 (PBST)] for 30–60 min before incubation 
with primary Brn-3b antibody (1:500) (overnight at 4° C). 
Following 5 washes in PBST, secondary antibody was 
incubated (1 hr, RT). After final washes, cells were 
mounted in fluorescent mounting medium with DAPI 
(Vector Laboratories). Images were captured using the 
ZEISS Axioskop microscope with Axiovision software 
(Zeiss).
Statistical analysis
Data was analysed using Graphpad Prism with the 
student’s t-test use for normal distribution or the Man–
Whitney U test where data was not normally distributed. 
Two-way analysis of variance (ANOVA) and post-hoc 
test (e.g. bonferroi) were used to determine whether the 
differences in the means of two or more factors were 
significant. All data in text and figures are presented as 
means ± SD with P < 0.05 indicating statistical significance 
(*P < 0.05). 
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